MD Anderson Cancer Center Department Chair Richard E. Champlin, M.D. Joins Actinium Pharmaceuticals, Inc.’s Iomab™-B Scientific Advisory Board

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Richard E. Champlin, M.D. of MD Anderson Cancer Center to its Scientific Advisory Board (SAB) for Iomab™-B, the Company’s lead radioimmunotherapy asset which is preparing to enter a Phase III pivotal trial. MD Anderson is one of the world’s most respected centers devoted exclusively to patient care, research, education and prevention.

Help employers find you! Check out all the jobs and post your resume.

Back to news